基于人群的有组织前列腺癌检测:对50岁男性首次邀请的结果
瑞典三个地区于2020-2022年邀请所有50岁男性参加有组织前列腺癌检测(OPT),68 060名受邀者中23 855名(35%)参与;696名(2.9%)PSA≥3 ng/ml,其中306名(44%)有活检指征、221名(32%)接受活检;活检发现93名(42%)为Gleason分级分组≥2(占PSA检测男性的0.39%),44名(20%)为Gleason分级分组1。结论认为OPT项目可行,MRI和PSA密度使超过半数PSA≥3 ng/ml者避免活检,但区域间诊断结果差异提示需标准化诊断路径组成部分。
要点
- 50岁男性受邀参与OPT的总体参与率为35%(23 855/68 060)。
- PSA≥3 ng/ml者占2.9%(696/23 855),其中44%(306/696)有活检指征、32%(221/696)接受活检。
- 活检者中42%(93/221)为Gleason分级分组≥2,占PSA检测男性的0.39%。
核心结论
- OPT项目可行且对诊断路径依从性良好。
- 使用MRI和PSA密度使超过半数PSA≥3 ng/ml的男性避免了活检。
- 区域间诊断结果差异显示需要标准化诊断路径的组成部分。
研究设计与样本
- 瑞典人口最多的三个地区于2020-2022年以信函邀请所有50岁男性参加OPT。
- PSA≥3 ng/ml者转诊接受前列腺磁共振成像(MRI);各区域PSA检测方法不同。
- PI-RADS 1-3且PSA密度≥0.15 ng/ml/cm3或PI-RADS 4-5者转诊接受活检;数据来自瑞典有组织前列腺癌检测登记处。
主要发现
- 68 060名受邀男性中23 855名(35%)参与。
- 696名(2.9%)PSA≥3 ng/ml,其中306名(44%)有活检指征、221名(32%)接受活检。
- 活检者中93名(42%)为Gleason分级分组≥2(占PSA检测男性的0.39%),44名(20%)为Gleason分级分组1。
- 多数癌症患者接受治愈性意向治疗(70%)或处于主动监测(28%)。
- 区域间PSA≥3 ng/ml比例范围为2.3%至4.0%,PI-RADS 4-5比例范围为12%至21%。
关键数值与推荐
- PSA≥3 ng/ml者转诊接受前列腺MRI。
- PI-RADS 1-3且PSA密度≥0.15 ng/ml/cm3或PI-RADS 4-5者转诊接受活检。
- 各区域PSA检测方法不同。
临床怎么用
- 原文未据此给出推荐。
局限性
- 结果仅适用于50岁早期男性的首次检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The European Union recently recommended evaluation of the feasibility of organised prostate cancer screening. In Sweden, regional population-based organised prostate cancer testing (OPT) programmes were introduced in 2020. OBJECTIVE: To describe initial participation rates and diagnostic outcomes. DESIGN, SETTING, AND PARTICIPANTS: The three most populated Swedish regions invited all men aged 50 yr to OPT by a letter in 2020-2022. Men with prostate-specific antigen (PSA) ≥3 ng/ml were referred for prostate magnetic resonance imaging (MRI). PSA assays differed across regions. Men with Prostate Imaging Reporting and Data System (PI-RADS) 1-3 and PSA density ≥0.15 ng/ml/cm3 or PI-RADS 4-5 were referred for a biopsy. Data were obtained from the Swedish Register for Organised Prostate Cancer Testing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall and regional participation rates, PSA distributions, PI-RADS score distributions, cancer detection, and treatment were evaluated. RESULTS AND LIMITATIONS: A total of 23 855 (35%) of 68 060 invited men participated; 696 (2.9%) had PSA ≥3 ng/ml, and of them, 306 (44%) had a biopsy indication and 221 (32%) had a biopsy. On biopsy, 93 (42%) had Gleason grade group ≥2 (0.39% of PSA-tested men) and 44 (20%) Gleason grade group 1 cancer. Most men with cancer had treatment with curative intent (70%) or were under active surveillance (28%). Across regions, proportions of men with PSA ≥3 ng/ml ranged from 2.3% to 4.0%, and those with PI-RADS score 4-5 ranged from 12% to 21%. A limitation is that results are applicable only to first testing of men in their early 50s. CONCLUSIONS: The OPT programmes are feasible with good compliance to the diagnostic pathway. The use of MRI and PSA density avoided a biopsy for over half of the men with PSA ≥3 ng/ml. Inter-regional differences in diagnostic outcomes show a need for standardisation of the diagnostic pathway's components. PATIENT SUMMARY: We report the diagnostic outcomes of inviting 68 000 50-yr-old men to organised prostate cancer testing.
引用
- Bratt O, Godtman RA, Jiborn T, et al. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. Eur Urol. 2023. PMID: 38042646. doi:10.1016/j.eururo.2023.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。